FDA to assess lonafarib via priority review process in progeria and progeroid laminopathies

The FDA aims to have reviewed the new drug application for use in the US of this inhibitor of farnesyltransferase for these conditions by the end of November this year. The EMA accepted a market authorisation application for use in the EU for this drug in April this year.


Biospace Inc.